Plasma Incretin Levels and Dipeptidyl Peptidase-4 Activity in Patients with Obstructive Sleep Apnea.
Incretin hormones, namely glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide/glucose-dependent insulinotropic polypeptide (GIP), and dipeptidyl peptidase-4 (DPP-4) activity are important factors in glucose metabolism and have not been investigated in patients with obstructive sleep apnea (OSA).



The objective of this study was to investigate the association between OSA and incretin and DPP-4 activity.



This study included 96 consecutive patients without diabetes who were suspected of having OSA. We investigated the fasting and post-prandial incremental area under the curve (IAUC) of GLP-1, GIP serum levels, and serum DPP-4 activity levels, as well as their association with OSA. Changes in clinical variables were evaluated in the 43 patients who continued continuous positive airway pressure therapy for 3 months.



Apnea-hypopnea index was an independent determining factor for fasting GLP-1 (β = 0.31; P = 0.0019) and IAUC GIP (β = -0.21; P = 0.037) after adjusting for known confounding factors. In those with very severe OSA (apnea-hypopnea index ≥50), the IAUCs for GLP-1 and GIP were significantly decreased, while fasting GLP-1 and fasting GIP were significantly increased. DPP-4 activity had no relation to OSA parameters or severity, while body mass index was significantly higher in those with severe OSA. Although significant changes in incretin secretion were not seen for 3 months after onset of continuous positive airway pressure therapy, the fasting GLP-1 level in the treated patients with severe OSA decreased to the same level as in untreated patients with normal to moderately severe OSA.



OSA is associated with elevated serum levels of the incretin hormones GLP-1 (fasting) and GIP (post-prandial) in patients without diabetes. A significant association between body mass index and DPP-4, which is said to exist in healthy persons, was not found in the patients with OSA. Fasting GLP-1 in patients without diabetes with OSA may influence fasting glucose levels.
1 Department of Respiratory Medicine.
Takeshi
T
Matsumoto
2 Department of Diabetes, Endocrinology and Nutrition, and.
Norio
N
Harada
1 Department of Respiratory Medicine.
Masanori
M
Azuma
3 Department of Respiratory Medicine, Red Cross Otsu Hospital, Otsu, Japan.
Yuichi
Y
Chihara
1 Department of Respiratory Medicine.
Kimihiko
K
Murase
1 Department of Respiratory Medicine.
Ryo
R
Tachikawa
1 Department of Respiratory Medicine.
Takuma
T
Minami
1 Department of Respiratory Medicine.
Satoshi
S
Hamada
4 Department of Respiratory Care and Sleep Control Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan; and.
Kiminobu
K
Tanizawa
4 Department of Respiratory Care and Sleep Control Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan; and.
Morito
M
Inouchi
4 Department of Respiratory Care and Sleep Control Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan; and.
Toru
T
Oga
1 Department of Respiratory Medicine.
Michiaki
M
Mishima
4 Department of Respiratory Care and Sleep Control Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan; and.
Kazuo
K
Chin
D000328:Adult; D000368:Aged; D018819:Dipeptidyl Peptidase 4 / Q000097:blood*; D005215:Fasting; D005260:Female; D005749:Gastric Inhibitory Polypeptide / Q000097:blood; D052216:Glucagon-Like Peptide 1 / Q000097:blood; D018149:Glucose Intolerance / Q000097:blood*; D006801:Humans; D054795:Incretins / Q000097:blood*; D007564:Japan; D008297:Male; D008875:Middle Aged; D012044:Regression Analysis; D020181:Sleep Apnea, Obstructive / Q000097:blood*
D054795:Incretins; D005749:Gastric Inhibitory Polypeptide; D052216:Glucagon-Like Peptide 1; D018819:Dipeptidyl Peptidase 4
gastric inhibitory polypeptide/glucose-dependent insulinotropic polypeptide; glucagon-like peptide-1; impaired glucose tolerance